DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/tmjv2f/seasonal_allergic) has announced the addition of the "Seasonal Allergic Rhinitis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Seasonal Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Allergic Rhinitis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Adamis Pharmaceuticals Corporation
- FAES Farma SA
- GlaxoSmithKline Plc
- Glenmark Pharmaceuticals Ltd.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical Co., Ltd.
- Shionogi & Co., Ltd.
- VentiRx Pharmaceuticals, Inc.
Drug Profiles
- (azelastine hydrochloride + mometasone furoate)
- APC-3000
- bepotastine besylate
- bilastine
- desloratadine
- GSP-301
- levocabastine hydrochloride
- ONO-4053
- S-555739
- VTX-1463
For more information visit http://www.researchandmarkets.com/research/tmjv2f/seasonal_allergic
